Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular degeneration
نویسندگان
چکیده
منابع مشابه
Treat and Extend Versus Treat and Observe Regimens in Wet Age-related Macular Degeneration Patients Treated with Ranibizumab: 3-year Surveillance Period
Copyright: © 2014 Calvo P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Treat and Extend Versus Treat and Observe Regimens in Wet Agerelated Macular Degeneration Patients Treated with Ranibizumab: 3-...
متن کاملAflibercept in exudative age related macular degeneration refractory to ranibizumab.
PURPOSE The aim of this study is to determine the effectiveness, safety and cost of aflibercept in the treatment of wet age-related macular degeneration (ARMD) refractory to ranibizumab. METHODS Retrospective observational study was conducted on patients diagnosed with wet ARMD, and previously treated with ranibizumab. Efficacy variables assessed were changes in visual acuity (BCVA) and anato...
متن کاملAflibercept for the treatment of neovascular age-related macular degeneration.
Age-related macular degeneration (AMD) can have devastating effects on vision, especially in its neovascular form. In the last decade, the use of intravitreal pharmacotherapy targeted to vascular endothelial growth factor (VEGF) has significantly improved the visual outcomes in patients with neovascular AMD. Although we have become accustomed to these unprecedented improvement outcomes, maintai...
متن کاملAflibercept for the Treatment of Age-Related Macular Degeneration
Aflibercept is a novel, recombinant, fusion protein that consists of portions of vascular endothelial growth factor (VEGF) receptor (R) 1 and VEGFR2 extracellular domains fused to the Fc portion of human immunoglobulin G1. It exhibits higher affinity for VEGF-A/-B and binds all the VEGF isoforms (VEGF-B and -C, placental growth factor). The efficacy of aflibercept was assessed in two randomized...
متن کاملTreatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept
A formulation of aflibercept for intravitreal injection (Eylea) is approved for the treatment of patients with exudative age-related macular degeneration (AMD). Aflibercept has a significantly higher affinity for Vascular endothelial growth factor (VEGF)-A compared with other monoclonal anti-VEGF antibodies. In addition to binding all VEGF-A isoforms, aflibercept also blocks other proangiogenic...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Acta Ophthalmologica
سال: 2017
ISSN: 1755-375X
DOI: 10.1111/aos.13607